Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 42

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 42
---
2024, a portion of his RSU awards (30,750 units) were accelerated to vest and the remainder of the unvested RSU awards (40,126 units) were |

| (8) | The performance-based restricted stock unit awards granted to Mr. Alder in December 2021 did not vest as the performance milestones were not achieved. The performance-based restricted stock unit awards were granted from the 2021 Inducement Plan. |

| (9) | Mr. Ballantyne’s equity grants were forfeited upon his resignation from employment with the Company effective as of March 1, 2024. |

The Company’s Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information

We do not have any formal policy that requires us to grant, or avoid granting, equity-based compensation to our executive officers at certain times.

Other than as reflected in the table below, no stock options were issued to executive officers in fiscal year 2024 during any period beginning four business days before the filing of a periodic report or current report disclosing material non-public information and ending one business day after the filing or furnishing of such report with the SEC.

| ​                              | ​ | ​        | ​ |              ​ | ​ |            ​ | ​ |          ​ | ​ |                                       ​ | ​ | ​ | ​ |
| ​                              | ​ | ​        | ​ |              ​ | ​ |            ​ | ​ |          ​ | ​ | Percentage Change in the Closing Market |   |   |   |
| ​                              | ​ | ​        | ​ |              ​ | ​ |            ​ | ​ |          ​ | ​ |  Price of the Securities Underlying the |   |   |   |
| ​                              | ​ | ​        | ​ |              ​ | ​ |            ​ | ​ |          ​ | ​ |        Award between the Trading Ending |   |   |   |
| ​                              | ​ | ​        | ​ |              ​ | ​ |            ​ | ​ |          ​ | ​ |     Immediately Prior to the Disclosure |   |   |   |
| ​                              | ​ | ​        | ​ |      Number of | ​ |     Exercise | ​ |          ​ | ​ |       of Material Nonpublic Information |   |   |   |
| ​                              | ​ | ​        | ​ |     Securities | ​ | Price of the | ​ | Grant Date | ​ |           and the Trading Day Beginning